Combined expression of urokinase-type plasminogen activator and proliferating cell nuclear antigen at the deepest invasive portion correlates with colorectal cancer prognosis

International Journal of Oncology

Volumn 10, Issue 1, 1997, Pages 125-129

  Tatsuta, Shigehiko ^a   Tanaka, Shinji ^a   Haruma, Ken ^a   Yoshihara, Masaharu ^a   Sumii, Koji ^a   Kajiyama, Goro ^a   Shimamoto, Fumio ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; PCNA; Prognosis; Urokinase type plasminogen activator

Indexed keywords

CYCLINE; UROKINASE;

ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; COLORECTAL CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031017765     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.1.125     Document Type: Article

References (22)

1. Peterson L, Lund L, Nielsen L, Dano K and Skriver L: One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 263: 11189-11195, 1988.
2. Blasi F and Verde P: Urokinase-dependent cell surface proteolysis and cancer. Semin Cancer Biol 1: 117-126, 1990.
3. Matrisian LM: The matrix-degrading metalloproteinases. Bioassays 14: 455-463, 1992.
4. Ossowski L: Invasion of connective tissue by human carcinoma cell lines-requirement for urokinase, urokinase receptor and interstitial collagenase. Cancer Res 52: 6754-6760, 1992.
5. Baker MS, Bleakley P, Woodrow GC and Doe WF: Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 50: 4676-4684, 1990.
6. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC and Miskin R: Effects of inhibitors of plasminogen activator, serine proteinase and collagenase IV on the invasion of basement membrane by metastatic cells. Cancer Res 48: 3307-3312, 1988.
7. Sier CFM, Verspaget HW, Griffioen G, Verheijen JH, Quax PHA, Dooijewaard G, Bruin PAF and Lamers CBHW: Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Gastroenterology 101: 1522-1528, 1991.
8. Sim PS, Stephens RW, Fayle DRH and Doe WF: Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps - quantitative expression of active and proenzyme. Int J Cancer 42: 483-488, 1988.
9. Appela E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G and Blasi F: The receptor-binding sequence of urokinase. J Biol Chem 262: 4437-4440, 1987.
10. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J and Goltzman D: An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 173: 1058-1064, 1990.
11. Celis JE and Celis A: Cell cycle-dependent variations in the distribution of the nuclear protein cyclin/proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 82: 3262-3266, 1985.
12. Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB and Watkins JA: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285-294, 1990.
13. Zuber M, Tan EM and Ryoji M: Involvement of proliferating cell nuclear antigen (cyclin) in DNA replication in living cells. Mol Cell Biol 9: 57-66, 1989.
14. Jaskulski D, de Riel JK, Mercer WE, Calabretta B and Baserga R: Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science 240: 1544-1546, 1988.
15. Teixeira CR, Tanaka S, Haruma K, Yoshihara M, Sumii K and Kajiyama G: Proliferating cell nuclear antigen (PCNA) expression at the invasive tumor margin predicts malignant potential of colorectal carcinomas. Cancer 73: 575-579, 1994.
16. Tanaka S, Haruma K, Tatsuta S, Hiraga Y, Teixeira CR, Shimamoto F, Yoshihara M, Sumii K and Kajiyama G: Proliferating cell nuclear antigen expression correlates with the metastatic potential of submucosal invasive colorectal carcinoma. Oncology 52: 134-139, 1995.
17. Teixeira CR, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G and Shimamoto F: The clinical significance of the histologic subclassification of colorectal carcinoma. Oncology 50: 495-499, 1993.
18. Tanaka S, Haruma K, Teixeira CR, Tatsuta S, Ohtsu N, Hiraga Y, Yosihara M, Sumii K, Kajiyama G and Shimamoto F: Endoscopic treatment of submucosal invasive colorectal carcinoma with special reference to risk factors for lymph node metastasis. J Gastroenterol 30: 710-717, 1995.
19. Jass JR and Sobin LH: Histological typing of intestinal tumours. In International Histological Classification of Tumours. 2nd edition, Springer, Berlin, 1989.
20. Kohga S, Harvey SR, Weaver R and Markus G: Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res 45: 1787-1796, 1985.
21. Buo L, Lyberg T, Jorgensen L, Johansen HT and Aasen AO: Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. Acta Pathol Microbiol Immunol Scand 101: 235-241, 1993.
22. Tan K, Powe DG, Gray T, Turner DR and Hewitt RE: Regional variations of urokinase-type plasminogen activator in human colorectal cancer: a quantitative study by image analysis. Int J Cancer 60: 308-314, 1995.